N-acetylcysteine for major depressive episodes in bipolar disorder;N-acetilcisteína para o tratamento de episódios de depressão maior no transtorno bipolar

Revista Brasileira de Psiquiatria

Volumn 33, Issue 4, 2011, Pages 374-378

  Magalhães, Pedro V ^a,b   Dean, Olívia M ^b,c   Bush, Ashley I ^b   Copolov, David L ^d   Malhi, Gin S ^e,f   Kohlmann, Kristy K ^b,c   Jeavons, Susan ^b,g   Schapkaitz, Ian ^b   Anderson Hunt, Murray ^b   Berk, Michael ^b,c,h  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g LA TROBE UNIVERSITY   (Australia)

^h THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

Acetylcysteine; Antioxidants; Bipolar disorder; Depression; Oxidative stress

Indexed keywords

ACETYLCYSTEINE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACETYLCYSTEINE; ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CHEMOTHERAPY, ADJUVANT; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84855821800     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462011000400011     Document Type: Article

References (35)

1. Ketter TA. Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder. J Clin Psychiatry. 2010;71(10):e27.
2. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143-57.
3. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB. Psychosocial disability in the course of bipolar I and II disorders-A prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322-30.
4. Sanchez-Moreno J, Martinez-Aran A, Tabares-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: An extensive review. Psychother Psychosom. 2009;78(5):285-97.
5. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163(9):1561-8.
6. El-Mallakh RS, Elmaadawi AZ, Loganathan M, Lohano K, Gao Y. Bipolar disorder: an update. Postgrad Med. 2010;122(4):24-31.
7. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175-9.
8. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-17.
9. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, Pasquali MA, Quevedo J, Gama CS, Post R. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry. 2010;15(8):784-6.
10. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, Moreira JC, de Bittencourt Pasquali MA, Fries GR, Quevedo J, Gama CS, Post R. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156-61.
11. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, Kauer-Sant'anna M, Grassi-Oliveira R, Post RM. Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32(4):675-92.
12. Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S, Berk M. A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice. Curr Med Chem. 2009;16(23):2965-76.
13. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78-86.
14. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29(7):346-51.
15. Choy KHC, Dean O, Berk M, Bush AI, van den Buuse M. Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one- treated rats. Eur J Pharmacol. 2010;649(1-3):224-8.
16. Dean O, Bush AI, Berk M, Copolov DL, van den Buuse M. Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacol Biochem Behav. 2010;97(2):293-300.
17. Fullerton JM, Tiwari Y, Agahi G, Heath A, Berk M, Mitchell PB, Schofield PR. Assessing oxidative pathway genes as risk factors for bipolar disorder. Bipolar Disord. 2010;12(5):550-6.
18. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14(8):1069-74.
19. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI. N-acetyl cysteine for depressive symptoms in bipolar disorder-A double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64(6):468-75.
20. Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S.Schapkaitz I, Anderson Hunt M, Berk M. Dimensions of improvement in a clinical trial of n-acetyl cysteine for bipolar disorder. Acta Neuropsychiatr. 2011;23(2):87-8.
21. Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011:129(1-3);317-20.
22. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. MINI - Mini International Neuropsychiatric Interview-English Version 5.0.0-DSM-IV. J Clin Psychiatry. 1998;59 Suppl 20:22-57.
23. Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB. The bipolar depression rating scale (BDRS): Its development, validation and utility. Bipolar Disord. 2007;9(6):571-9.
24. Berk M, Malhi GS, Mitchell PB, Cahill CM, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M. Scale matters:he need for a Bipolar Depression Rating Scale (BDRS). Acta Psychiatr Scand Suppl. 2004;422:39-45.
25. Montgomery SA, Asberg M. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
26. Young RC, Biggs JT, Ziegler VE, Meyer DA. Rating scale for mania-reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
27. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-71.
28. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The longitudinal interval follow-up evaluation-a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6):540-8.
29. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire-a new measure. Psychopharmacol Bull. 1993;29(2):321-36.
30. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453-73.
31. Henderson AR. The bootstrap: A technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clin Chim Acta. 2005;359(1-2):1-26.
32. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biological Reviews. 2007;82(4):591-605.
33. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry. 2007;68(8):1230-6.
34. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004:56(1);54-60.
35. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;16(3):564-6.